Search

Your search keyword '"Staumont-Sallé, D."' showing total 501 results
Start Over Author "Staumont-Sallé, D."
501 results on '"Staumont-Sallé, D."'

1. French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis)

Author

Ingen-Housz-Oro, S., Matei, I., Gaillet, A., Gueudry, J., Zaghbib, K., Assier, H., Hua, C., Bensaid, B., Colin, A., Ouedraogo, R., Redlich, J., Courtois, E., Chazelas, K., Sbidian, E., Nakad, L., Bequignon, E., Terkmane, N., Gaultier, F., Schlemmer, F., Do-Pham, G., Barbaud, A., Lebrun-Vignes, B., Hoffmann, C., Mahé, P.-J., Le Floch, R., Bernier, C., Vabres, B., Milpied, B., Delcampe, A., Tétart, F., Tauber, M., Staumont-Sallé, D., Dezoteux, F., Descamps, V., Misery, L., Bursztejn, A.-C., Dereure, O., Amazan, E., Le Bidre, E., Le Pallec, S., Lagier, C., Laroche, A., Ferrat, E., Wolkenstein, P., and de Prost, N.

Published
2024
Full Text
View/download PDF

2. Promoting clinical research in community-based practice: Threats and opportunities

Author

Poizeau, F., Maruani, A., Staumont-Sallé, D., Jouan, N., Ly, S., Schollhammer, M., Reverte, M., Dibao-Dina, C., Duong, T.-A., Matard, B., Penso-Assathiany, D., Dupuy, A., Carriot, M., Seï, J.-F., Corgibet, F., Guillot, B., Barbarot, S., Leducq, S., Bertolotti, A., Tannous, J., Chaby, G., Jullien, D., Pépin, E., Quéreux, G., Beylot-Barry, M., and Chosidow, O.

Published
2024
Full Text
View/download PDF

3. Promouvoir la recherche clinique en dermatologie libérale : freins et opportunités

Author

Poizeau, F., Maruani, A., Staumont-Sallé, D., Jouan, N., Ly, S., Schollhammer, M., Reverte, M., Dibao-Dina, C., Duong, T.-A., Matard, B., Penso-Assathiany, D., Dupuy, A., Carriot, M., Seï, J.-F., Corgibet, F., Guillot, B., Barbarot, S., Leducq, S., Bertolotti, A., Tannous, J., Chaby, G., Jullien, D., Pépin, E., Quéreux, G., Beylot-Barry, M., and Chosidow, O.

Published
2024
Full Text
View/download PDF

11. Quand mettre en route un traitement systémique dans la dermatite atopique ?

Author

Staumont-Sallé, D.

Abstract

Malgré l’arrivée de nombreux nouveaux traitements dans la dermatite atopique, de nombreux patients, adultes et enfants, restent en errance thérapeutique et ne bénéficient pas d’un traitement suffisant pour contrôler de façon durable leur maladie. Il est dont important d’identifier les patients qui ont besoin d’un traitement systémique quand les traitements topiques ne sont plus adaptés. La décision de mise en route d’un traitement systémique doit reposer sur plusieurs facteurs qui vont bien au-delà de l’AMM et du remboursement d’une molécule. Cette démarche implique en effet une évaluation multidimensionnelle de la sévérité de la maladie, dans laquelle les scores ont une place s’ils sont faisables en pratique et s’ils tiennent compte de la perception qu’a le patient de ses symptômes et du retentissement de la maladie sur sa qualité de vie. La décision médicale partagée permet d’harmoniser les attentes du médecin et du patient (ou de son entourage chez l’enfant) et de définir de manière collaborative un objectif thérapeutique adapté et réaliste. Identifier précocement un patient éligible à un traitement systémique requiert une formation adéquate en soins primaires (médecin traitant, généraliste ou pédiatre) et une bonne coopération ville-hôpital pour le dermatologue ou l’allergologue afin de faciliter le parcours patient et de garantir son accès « au bon traitement au bon moment ».

Published
2024
Full Text
View/download PDF

15. Retrospective study on the association of human herpesvirus reactivation with severe DRESS: A description of blood and skin reactivations.

Author

Marcombes, C., Ingen‐Housz‐Oro, S., Dezoteux, F., Staumont‐Sallé, D., Milpied, B., Tetart, F., de Prost, N., Fourati, S., Ortonne, N., Kasimir, F., Prusty, B. K., and Descamps, V.

Subjects
INTENSIVE care units, SKIN biopsy, VIRUS reactivation, BLOOD sampling, VIRAL proteins, AUJESZKY'S disease virus
Abstract

Background: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe adverse event (mortality of 10%). Its pathophysiology involves herpesviruses, particularly HHV‐6, but the exact mechanisms are still poorly understood. Objective: To describe severe cases of DRESS and especially their association with herpesvirus reactivation. Methods: This study was a multicentre case series conducted between 2007 and 2021 at five University Hospital Centres in France. The study included patients who had severe DRESS, which was defined as death, transfer to the intensive care unit (ICU), or severe damage to internal organs. We excluded patients without blood PCR sample, without a drug formally attributed or with RegiSCAR score < 6. We collected data on severity, causative drug, associated visceral damage and results of viral blood PCRs. HHV‐6 reactivation was studied in skin biopsies by detection of small non‐coding transcripts (HHV‐6 miR‐aU14) and a late viral protein (GP82/105). Results: Fifty‐two patients were included (29 female, median age 62, interquartile range (IQR) [37;72]). Eight patients (15%) died, 13 (27%) were admitted to ICU. Most patients (n = 34; 65%) had multisystem involvement: most frequent was liver (n = 46; 88%), then renal failure (n = 24; 46%). Forty patients (77%) had at least one blood viral reactivation among HHV‐6, EBV or CMV, of which 21 (53%) had at least two. Median time of blood HHV‐6 reactivation was 24 days (IQR [20;35]). HHV‐6 reactivation was demonstrated in 15 out of 20 skin biopsies, with a median time of 11 days [9;17]. Conclusions: We confirmed the high rate of HHV‐6 reactivation in severe DRESS and demonstrated cutaneous HHV‐6 reactivation using small non‐coding transcripts (HHV‐6 miR‐aU14), which preceded viral PCR positivity in blood. These results suggest that HHV‐6 reactivation during DRESS may start in skin. Furthermore, search for miR‐aU14 in skin biopsy could become a useful diagnostic tool for early detection of HHV‐6 reactivation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Efficacité de l’abrocitinib et du dupilumab sur les taux d’éosinophiles chez les patients atteints de dermatite atopique modérée à sévère et de comorbidités atopiques de type asthme et rhinite allergique : analyse post-hoc de JADE COMPARE

Author

Staumont-Sallé, D., primary, Chan, G., additional, Clibborn, C., additional, Feeney, C., additional, Bourne-Chastel, A., additional, Misery, L., additional, Nosbaum, A., additional, Seneschal, J., additional, Soria, A., additional, and Zhang, F., additional

Published
2022
Full Text
View/download PDF

27. Étude descriptive multicentrique des schémas d’adaptation en cas de réponse inadéquate au dupilumab dans la dermatite atopique en France

Author

Strizzolo, R., primary, Soria, A., additional, Jachiet, M., additional, Tauber, M., additional, Seneschal, J., additional, Clément, A., additional, Staumont-Sallé, D., additional, Barbarot, S., additional, Raison Peyron, N., additional, Viguier, M., additional, Mallet, S., additional, and Du Thanh, A., additional

Published
2022
Full Text
View/download PDF

28. Efficacité et tolérance des inhibiteurs de Janus kinase dans le traitement de la dermatite atopique modérée à sévère de l’adulte réfractaire à d’autres systémiques: expérience en vraie vie

Author

Vanlerberghe, J., primary, Dezoteux, F., additional, Martin, C., additional, Jachiet, M., additional, Soria, A., additional, Tétart, F., additional, Modeste-Duval, A.B., additional, Bursztejn, A.C., additional, Misery, L., additional, Aubin, F., additional, Lasek, A., additional, Leleu, C., additional, Du Thanh, A., additional, Pasteur, J., additional, Pralong, P., additional, Nosbaum, A., additional, Droitcourt, C., additional, Viguier, M., additional, Tauber, M., additional, Seneschal, J., additional, Barbarot, S., additional, and Staumont-Sallé, D., additional

Published
2022
Full Text
View/download PDF

29. Impact de la dermatite atopique sur les conjoints des patients

Author

Misery, L., primary, Seneschal, J., additional, Corgibet, F., additional, Halioua, B., additional, Marquie, A., additional, Merhand, S., additional, Le Fur, G., additional, Bergqvist, C., additional, Taieb, C., additional, Staumont-Sallé, D., additional, Ezzedine, K., additional, and Richard, M.A., additional

Published
2022
Full Text
View/download PDF

31. Eczéma paradoxal sous biothérapie ciblant l’axe IL-5/IL-5R

Author

Bourdenet, V., primary, Devouassoux, G., additional, Antoine, B., additional, Bernier, C., additional, Carpentier, O., additional, Chenivesse, C., additional, Du Thanh, A., additional, Fry, S., additional, Gadiolet, Y., additional, Gamez, A.S., additional, Kelkel, E., additional, Larousse, M., additional, Soria, A., additional, Staumont-Sallé, D., additional, Streker, A., additional, Valois, A., additional, Xavier, B., additional, Freymont, N., additional, and Nosbaum, A., additional

Published
2022
Full Text
View/download PDF

38. Étude de survie du traitement par omalizumab dans une cohorte multicentrique française de patients atteints d’urticaire chronique

Author

Litovsky, J., primary, Paryl, M., additional, Hacard, F., additional, Tétart, F., additional, Boccon Gibod, I., additional, Dezoteux, F., additional, Staumont-Sallé, D., additional, Darrigade, A.S., additional, Doutre, M.S., additional, Milpied, B., additional, Soria, A., additional, Amsler, E., additional, Bernier, C., additional, Perrot, J.L., additional, Raison Peyron, N., additional, Mura, T., additional, Grosjean, J., additional, and Du Thanh, A., additional

Published
2022
Full Text
View/download PDF

44. Éruptions eczématiformes chroniques du sujet âgé : quelle imputabilité médicamenteuse ?

Author

Bouteiller, J., primary, Grosjean, J., additional, Delaunay, J., additional, Jachiet, M., additional, Bara, C., additional, Nosbaum, A., additional, Bouschon, P., additional, Milpied, B., additional, Oro, S., additional, Assier, H., additional, Guelimi, R., additional, Valois, A., additional, Viguier, M., additional, Dezoteux, F., additional, Staumont-Sallé, D., additional, Boulard, C., additional, Brenaut, E., additional, Morice, C., additional, Raison Peyron, N., additional, Joly, P., additional, and Tetart, F., additional

Published
2022
Full Text
View/download PDF

45. Blépharo-conjonctivites sous dupilumab : recommandations du groupe CEDRE. Dermatite atopique, conjonctivites et dupilumab

Author

Doan, S., Arnould, L., Febvay, C., Fournié, P., Gueudry, J., Labalette, P., Ouilhon, C., Tran, T.-H.-C., Vabres, B., Barbarot, S., Bouaziz, J.-D., Du-Thanh, A., Jachiet, M., Seneschal, J., Soria, A., Staumont-Sallé, D., Baudouin, C., Mortemousque, B., Service d'ophtalmologie [Hopital Bichat - Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Service d'Ophtalmologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Ophtalmologie [Hôpital Edouard Herriot - HCL]], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Université Catholique de Lille - Faculté de Médecine, Maïeutique, Sciences de la santé (FMMS), Institut Catholique de Lille (ICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pathogénèse et contrôle des infections chroniques (PCCI), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Inserm U1035, Biotherapies des Maladies Genetiques et Cancers, Univ Bordeaux, CHU de Bordeaux, Pole de Biologie et Pathologie, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO)

Subjects
Dermatite atopique, Conjonctivite, Atopic Dermatitis, Dupilumab, Conjunctivitis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Dupilumab is a recombinant monoclonal IgG4 type antibody which inhibits IL4 and IL13 signaling. It is indicated in moderate to severe atopic dermatitis (AD) in adults and adolescents over 12 years of age. Its side effects include conjunctivitis and blepharoconjunctivitis, affecting between 4.7% and 28% of patients depending on the study. The incidence of conjunctivitis in patients treated with dupilumab for AD appears to be higher than placebo in clinical studies. This increase was not observed in patients treated with dupilumab for asthma or sinonasal polyposis. The risk factors for conjunctivitis in patients with AD are disease severity, pre-existence of conjunctivitis and low concentrations of dupilumab, but the pathophysiology of this disease is poorly understood. A literature search carried out in April and May 2020 showed an increase in the number of publications on the subject, but there are currently no official joint dermatologist-ophthalmologist recommendations for prevention and management. The objective of this article is to provide an overview of the status of this subject, to address the main questions raised by this type of conjunctivitis and to suggest a course of action for starting and continuing treatment with dupilumab in patients with AD, according to the recommendations of the French Ophthalmologist/Dermatologist group CEDRE.

Published
2022

48. Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy

Author

Dezoteux, F., El Mesbahi, S., Tedbirt, B., Grosjean, J., Gautier, S., Lannoy, D., Nassar, C., Tétart, F., Staumont‐Sallé, D., Département de Dermatologie [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), CHU de Rouen, Département d’informatique et d’information médicales, Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Centre Régional de PharmacoVigilance Nord-Pas-de-Calais [CHU Lille] (CRPV), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université Lille 2 - Faculté de Médecine, CHU Lille, Institut de Pharmacie, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), and Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Abstract

International audience; The use of immunomodulatory and/or immunosuppressive therapy (IT) is increasingly common in the management of chronic inflammatory disease. Skin reactions to any drug (IT or not) are not rare in these patients, justifying allergological investigations. The influence of IT on allergological tests for drugs is not clearly described. IT cannot be interrupted due to the underlying disease. The data assessing the benefit and the safety of allergological test for drug allergy in patients under IT are missing.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results